Evidence map›Paper›PMID 19416892›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins.

Kathryn L Schornberg, Charles J Shoemaker, Derek Dube, Michelle Y Abshire, Sue E Delos, Amy H Bouton, Judith M White

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 91 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Targeting integrin pathways: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2023
    Review
  11. Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023
    Article
  12. Article
  13. Integrins as Therapeutic Targets for SARS-CoV-2.Frontiers in cellular and infection microbiology · 2022
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathryn L SchornbergDepartment of Microbiology, University of Virginia, Charlottesville, VA 22908-0734, USA.
Charles J Shoemaker
Derek Dube
Michelle Y Abshire
Sue E Delos
Amy H Bouton
Judith M White
Icahn School of Medicine at Mount Sinai · USUniversity of Virginia · US

Funding

Vaccine strategy for broad spectrum protection agains non-typhoidal salmonellU54AI057168 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2003 to 2013
$91.5M
INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
UVA Digestive Health Research CenterP30DK067629 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI COMINELLI, FABIO · 2004 to 2008
$5.6M
Global Biothreats Training ProgramT32AI055432 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI CRISS, ALISON K, PETRI, WILLIAM A · 2003 to 2022
$4.0M
MOLECULAR MECHANISMS OF VIRAL MEMBRANE FUSION PROTEINSR01AI022470 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI WHITE, JUDITH M. · 1985 to 2009
$3.4M
Mechanistic aspects of integrin-mediated Yersinia uptakeR01AI050733 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI BOUTON, AMY H · 2003 to 2007
$1.4M
NIAID NIH HHS 5T32 AI055432NIAID NIH HHS 5T32 AI07046NIAID NIH HHS AI050733NIAID NIH HHS AI22470NIAID NIH HHS R01 AI022470NIAID NIH HHS R01 AI050733NIAID NIH HHS T32 AI007046NIAID NIH HHS T32 AI055432NIAID NIH HHS U54 AI057168NIAID NIH HHS U54 AI7168NIDDK NIH HHS P30 DK067629
6 · The paper itself

Abstract

Integrins are involved in the binding and internalization of both enveloped and nonenveloped viruses. By using 3 distinct cell systems-CHO cells lacking expression of alpha(5)beta(1)-integrin, HeLa cells treated with siRNA to alpha(5)-integrin, and mouse beta(1)-integrin knockout fibroblasts, we show that alpha(5)beta(1)-integrin is required for efficient infection by pseudovirions bearing the ebolavirus glycoprotein (GP). These integrins are necessary for viral entry but not for binding or internalization. Given the need for endosomal cathepsins B and L (CatB and CatL) to prime GPs for fusion, we investigated the status of CatB and CatL in integrin-positive and integrin-negative cell lines. Alpha(5)beta(1)-Integrin-deficient cells lacked the double-chain (DC) forms of CatB and CatL, and this correlated with decreased CatL activity in integrin-negative CHO cells. These data indicate that alpha(5)beta(1)-integrin-negative cells may be refractory to infection by GP pseudovirions because they lack the necessary priming machinery (the double-chain forms of CatB and CatL). In support of this model, we show that GP pseudovirions that have been preprimed in vitro to generate the 19-kDa form of GP overcome the requirement for alpha(5)beta(1)-integrin for infection. These results provide further support for the requirement for endosomal cathepsins for ebolavirus infection, identify the DC forms of these cathepsins as previously unrecognized factors that contribute to cell tropism of this virus, and reveal a previously undescribed role for integrins during viral entry as regulators of endosomal cathepsins, which are required to prime the entry proteins of ebolavirus and other pathogenic viruses.

Indexed as

AnimalsCathepsinsCHO CellsCricetinaeCricetulusEbolavirusEndosomesFibroblastsHeLa CellsHumansIntegrin alpha5beta1IntegrinsMiceMice, KnockoutModels, BiologicalCathepsinsIntegrin alpha5beta1Integrins

Identifiers

PMID19416892
PMCPMC2683081
OpenAlexW2153760837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.